西格列汀与二甲双胍治疗初诊T2MD患者各30例临床疗效及安全性比较

Comparison of clinical efficacy and safety of sitagliptin and metformin in the treatment of newly diagnosed T2MD patients with 30 cases respectively

目的:探讨西格列汀与二甲双胍对初诊2型糖尿病(T2DM)患者的临床疗效及安全性。方法:将60例初诊T2MD患者随机分为治疗组1和治疗组2,治疗组1口服西格列汀片,治疗组2口服二甲双胍片,比较两组治疗效果。结果:治疗12周后,两组患者的FBG、2 h PG、Hb A1c、BMI比治疗前均有明显下降(P<0.05),但两组下降幅度差异无统计学意义(P>0.05)。治疗后两组在血脂、血常规、血压、肝肾功能、不良反应等方面差异无统计学意义(P>0.05)。结论:使用西格列汀治疗T2MD与二甲双胍比较,疗效、安全性基本相当,但其价格较贵,性价比较低。

Objective:To explore the clinical efficacy and safety of sitagliptin and metformin in the treatment of newly diagnosed T2 MD patients.Methods:60 cases of newly diagnosed T2 MD patients were selected.They were randomly divided into the treatment group and the control group.The treatment group were given sitagliptin,and the control group were given metformin,then we compared the therapeutic effect of the two groups.Results:After 12 weeks of treatment,compared with before treatment,FBG,2h PG,Hb A1 c,BMI of two groups of patients were decreased significantly(P<0.05),but there was no significant difference between the two group(P>0.05).After treatment,the two groups in blood lipids,blood routine,liver and kidney function,blood pressure,adverse reaction were no significant difference(P>0.05).Conclusion:Compared with metformin,sitagliptin was used to treat T2 MD,the efficacy and safety were basically the same,but the price was more expensive,the cost performance was low.